Literature DB >> 29294167

Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers.

Nishikant Avinash Damle1, Chandrasekhar Bal2, Tejesh Pratap Singh2, Ravikant Gupta2, Sreenivasa Reddy2, Rajeev Kumar2, Madhavi Tripathi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29294167     DOI： 10.1007/s00259-017-3904-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?

Authors:  Sameer Kamalakar Taywade; Nishikant Avinash Damle; Chandrasekhar Bal
Journal:  Clin Nucl Med       Date:  2016-05       Impact factor: 7.794

2.  First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.

Authors:  Frederik A Verburg; Thomas Krohn; Alexander Heinzel; Felix M Mottaghy; Florian F Behrendt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-28       Impact factor: 9.236

3.  Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone.

Authors:  Sophie Bourgeois; Pieterjan Gykiere; Lode Goethals; Hendrik Everaert; Frank W De Geeter
Journal:  Clin Nucl Med       Date:  2016-11       Impact factor: 7.794

4.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

5.  Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer.

Authors:  Kenneth R Noss; Steven A Wolfe; Sidney R Grimes
Journal:  Gene       Date:  2002-02-20       Impact factor: 3.688

6.  Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.

Authors:  Susanne Lütje; Benedikt Gomez; Joseph Cohnen; Lale Umutlu; Martin Gotthardt; Thorsten D Poeppel; Andreas Bockisch; Sandra Rosenbaum-Krumme
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

7.  PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT.

Authors:  Thorsten Derlin; Hans-Heinrich Kreipe; Udo Schumacher; Bisharah Soudah
Journal:  Clin Nucl Med       Date:  2017-03       Impact factor: 7.794

8.  Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA-HBED-CC in a Benign Thyroid Nodule.

Authors:  Nishikant Avinash Damle; Madhavi Tripathi; Partha Sarathi Chakraborty; Manas Kumar Sahoo; Chandrasekhar Bal; Shipra Aggarwal; Geetanjali Arora; Praveen Kumar; Rajeev Kumar; Ravikant Gupta
Journal:  Nucl Med Mol Imaging       Date:  2016-03-22

9.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

10.  Expression of prostate-specific membrane antigen in normal and malignant human tissues.

Authors:  Yoshihisa Kinoshita; Katsuyuki Kuratsukuri; Steve Landas; Katsumi Imaida; Peter M Rovito; Ching Y Wang; Gabriel P Haas
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282
  10 in total
  2 in total

Review 1.  Molecular Imaging and Theragnostics of Thyroid Cancers.

Authors:  Luca Giovanella; Desiree' Deandreis; Alexis Vrachimis; Alfredo Campenni; Petra Petranovic Ovcaricek
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

Review 2.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.